Clinical Trial Update: Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission [Phase 1, Phase 2]

View source ↗

Summary

Withdrawal of a Phase 1/2 trial evaluating a cancer vaccine therapy in combination with the IDO1 inhibitor epacadostat (INCB024360) for epithelial ovarian cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Epacadostat (epacadostat)
• Vaccine therapy

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1, Phase 2 | Status: WITHDRAWN